Jennifer L. Hundley, MD, Christie L

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis is associated with lipid abnormalities at the onset of skin disease Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Cutaneous myiasis associated with scalp psoriasis

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs Joseph F. Fowler, MD, Arindam Ghosh,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis Federica Ricceri, MD, Leonardo.

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Pediatric teledermatology: Observations based on 429 consults

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Pilot study of a skin cancer education curriculum for medical students

Pain and nonmelanoma skin cancer in transplant patients

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Plasma β-endorphin levels in frequent and infrequent tanners before and after ultraviolet and non-ultraviolet stimuli Mandeep Kaur, MD, Anthony Liguori,

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Reply to: “A note on normality”

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Topical tacrolimus for chronic actinic dermatitis

Adherence to topical hydrocortisone 17-butyrate 0

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Seasonal patterns in alopecia areata, totalis, and universalis

Appearance of lentigines in psoriasis patients treated with apremilast

Medicaid acceptance among pediatric dermatologists

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents Jennifer.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Prevalence of self-report photosensitivity in cutaneous lupus erythematosus Kristen Foering, BS, Renato Goreshi, MD, Rachel Klein, MD, Joyce Okawa, RN,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Presentation transcript:

Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life Jennifer L. Hundley, MD, Christie L. Carroll, MD, Wei Lang, PhD, Beverly Snively, PhD, Gil Yosipovitch, MD, Steven R. Feldman, MD, PhD, Joseph L. Jorizzo, MD Journal of the American Academy of Dermatology Volume 54, Issue 2, Pages 217-220 (February 2006) DOI: 10.1016/j.jaad.2004.12.015 Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Physician's Global Assessment (PGA) compared with quality of life (QOL) measures. There is greater QOL impairment for patients with more severe disease. QOL impact of dermatomyositis was assessed for patients at different levels of disease severity. There was clinically significant degree of QOL impairment at all levels of disease severity. Greater disease severity was associated with worse QOL. DLQI, Dermatology Life Quality Index. Journal of the American Academy of Dermatology 2006 54, 217-220DOI: (10.1016/j.jaad.2004.12.015) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Comparision of Skindex-16 subscales among dermatomyositis, dermatitis, and psoriasis. Skindex-16 scores for patients with dermatomyositis were compared with published data on dermatitis and psoriasis.11 All scores were normalized to a 0-to-100 scale for comparison. Journal of the American Academy of Dermatology 2006 54, 217-220DOI: (10.1016/j.jaad.2004.12.015) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions